BioSpace

BioSpace stands out as the top online hub for life science professionals, offering the latest industry news and career opportunities. With a rich history spanning more than 30 years, BioSpace has been dedicated to connecting talented individuals with job openings in the biotechnology and pharmaceutical sectors. Moreover, it has fostered better communication and collaboration among leaders in the biopharmaceutical field, enhancing discovery and innovation.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#70282

United States

#18685

Science and Education/Biology

#22

Traffic sources

Monthly visitors

Articles

Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - BioSpace

1 day ago | biospace.com
Galapagos Takes Dramatic U-Turn, Ditching Spinout Plan, Cell Therapy and CEO Stoffels

2 days ago | biospace.com | Annalee Armstrong

After some additional thought and market developments, Galapagos is reversing course on a series of plans that involved spinning out a portion of the company and finding a new CEO over the next year. Paul Stoffels will still exit the company, just sooner than expected. And the Belgian biotech will explore the potential sale of a clutch of cell therapy assets, which Stoffels brought into the company’s fold through a series of acquisitions over the past three years.
Trump’s Drug Pricing Order ‘More Bark Than Bite’

3 days ago | biospace.com | Annalee Armstrong

President Donald Trump’s executive order on drug pricing contains little detail about how exactly it will be implemented but may still fall in the “better than feared” category for the biopharma industry, according to analysts. The splashy announcement from the White House left Wall Street wanting more details. BMO Capital Markets analysts suggested that the order was “more bark than bite,” with questionable legal roots. “The announcement represents more of a headline risk vs.
White House Unwraps Massive Drug Pricing Policy, Touching All Corners of Pharma

3 days ago | biospace.com | Annalee Armstrong

The White House has announced a sweeping drug pricing policy package that will touch all edges of the pharmaceutical industry. The executive order to be signed by President Donald Trump Monday morning will affect drug prices from Medicare to the private markets and could impact various industry operations, including how biopharma companies source their drugs and how they protect their intellectual property.
Opinion: Bringing Neurological Disease Into the Age of Precision Medicine

4 days ago | biospace.com | John McDonough

In the U.S., we’ve recently seen remarkable progress in developing therapeutics for diseases like Alzheimer’s, where no approved disease-slowing treatments previously existed. While breakthroughs such as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla have led to modest improvements in slowing cognitive decline in Alzheimer’s patients, there remains a need for safer, more effective and more targeted medications that treat the underlying causes of disease.
Biopharma Targets an HIV Cure as NIH Funding Cuts Threaten To Derail Progress

4 days ago | biospace.com | Heather McKenzie

Since Donald Trump took office in January, the National Institutes of Health has seen its funding cut for numerous HIV studies, alarming researchers and likely reducing the chances of achieving the president’s own 2019 goal of ending HIV in the U.S. by 2030. Against this backdrop, biopharma companies such as Gilead Sciences and Immunocore are pursuing the holy grail—a cure. Medicine has made considerable strides against HIV since the advent of the epidemic in 1981.
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA

6 days ago | biospace.com | Annalee Armstrong

This deep dive was originally published Apr. 2, 2025 as a special edition of Biopharm Executive. Subscribe to Biopharm Executive to receive market insights, deals, business stories and deep dives into key policy issues impacting biopharma. Peter Marks, the venerable head of the FDA’s Center for Biologics Evaluation and Research, has been forced out.
Rest Up, Biopharma. Trump’s Drug Pricing Policy Is Coming on Monday

6 days ago | biospace.com | Annalee Armstrong

The biopharma world has been waiting with bated breath to see what President Donald Trump will do with the Inflation Reduction Act. Next week, we may finally know, as Trump teased in the Oval Office on Monday that a major drug pricing initiative is coming next week. The IRA has been extremely maligned by the industry, particularly the “pill penalty,” referring to the IRA’s longer period of protection from price negotiations for biologics than for small molecules.
Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM

6 days ago | biospace.com | Tristan Mañalac

Sanofi has turned its back on its partner IGM Biosciences, forcing the small California biotech to enact drastic strategic measures, including an 80% reduction in force. IGM made the announcement in an SEC document on Thursday, noting that Sanofi had informed it of the decision to walk away on Monday. The contract will formally end 30 days after the notice.
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews

6 days ago | biospace.com | Tristan Mañalac

In a bid to support regulatory review, the FDA expects to deploy artificial intelligence across all of its centers by the end of June, the agency announced Thursday. The announcement comes as the FDA completes its pilot scientific review using a generative AI model. “I was blown away by the success of our first AI-assisted scientific review pilot,” Commissioner Marty Makary said in a statement on Thursday, though the agency did not provide specific details about the project.